This article seeks to summarize what Brexit could mean for the U.K. and EU pharmaceutical and medical device sectors.
The U.K. government is expected to invoke Article 50 of the Lisbon Treaty by notifying the EU Council of its intention to leave the EU in early 2017. If no agreement is reached within two years of the notification, then EU laws cease to apply in the U.K. The two-year period may only be extended if the European Council unanimously agrees.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
